Middle East respiratory syndrome: obstacles and prospects for vaccine development.
Expert Rev Vaccines
; 14(7): 949-62, 2015 Jul.
Article
em En
| MEDLINE
| ID: mdl-25864502
ABSTRACT
The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates the in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas Virais
/
Infecções por Coronavirus
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article